The US FDA approved Ogsiveo on 27 November to treat adults with progressing desmoid tumors who require systemic treatment. The drug will be available within five to 10 days.
SpringWorks sets a list price of $29,000 for a 30-day supply and the company said it has had favorable discussions to date with commercial payers covering nearly all US patients.
Ogsiveo is the first FDA-approved option for desmoid tumors, which currently are treated with surgery or off-label drugs.
Nirogacestat also is being developed in combination with anti-BCMA therapies for multiple myeloma and as a monotherapy for ovarian granulosa cell tumors; data in both settings are due later in 2024.

SpringWorks’ Ogsiveo Is First-Ever US FDA-Approved Drug For Desmoid Tumors

Nirogacestat Also In Anti-BCMA Combo, Ovarian Cancer Studies